U.S. guidelines started discouraging prophylactic low-dose aspirin for adults over 70 in 2019. The U.S. Preventive Services ...

PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...

Symptomatic people with evidence of coronary artery disease on imaging significantly benefited from statin use while those ...

In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...

The Primary Oral Insulin Trial (POInT) investigates whether type 1 diabetes in at-risk children can be prevented through oral ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and ...

Rybelsus is now also indicated for cardiovascular risk reduction in adults with Type 2 diabetes who are at high risk, ...

First results of the Primary Oral Insulin Trial (POInT) mark an important step towards the prevention of type 1 diabetes, pointing future efforts to personalized strategies. The group led by ...